New Delhi: The Russian Direct Investment Fund (RDIF) stated on Sunday that the Sputnik V vaccine demonstrated a higher or equal tolerability profile in people above the age of 60 years, during inoculation campaign in San-Marino.
As per an official release, the Sputnik V vaccine has shown strong efficacy against hospitalization and tolerability among the elderly population in the country.
The study was conducted among people in San Marino who received two doses of Sputnik V beginning March 4 to April 8. The results of the study were published in EClinicalMedicine, an open-access clinical journal published by The Lancet.
Continue Reading
